Popular Weight-Loss Drugs May Reduce Breast Cancer Risk
熱門減肥藥物或可降低乳癌風險
更新於: 2026年6月7日 上午08:45
Recent research presented at the 2026 American Society of Clinical Oncology Annual Meeting has sparked excitement regarding a potential link between popular weight-loss drugs and breast cancer prevention.
在2026年美國臨床腫瘤學會(American Society of Clinical Oncology)年會上發表的一項最新研究，引發了對於熱門減肥藥物與乳癌預防之間潛在關聯的熱烈討論。
GLP-1 receptor agonists, such as Ozempic and Wegovy, are commonly used for obesity management, but a study of over 110,000 women aged 45-80 suggests they might offer additional health benefits.
類昇糖素胜肽-1(GLP-1)受體致效劑，例如Ozempic和Wegovy，常用於肥胖管理，但一項針對超過11萬名45至80歲女性的研究顯示，它們可能提供額外的健康益處。
Findings indicate that women prescribed these medications were approximately 30% less likely to be diagnosed with breast cancer.
研究結果指出，開立這些藥物的女性，被診斷出罹患乳癌的機率約降低了30%。
Researchers suggest several potential biological mechanisms for this protective effect.
研究人員提出了幾種可能的生物機制來解釋這種保護作用。
Sustained weight loss helps lower estrogen production in adipose tissue, while the drugs' ability to reduce systemic inflammation and improve insulin resistance may hinder cancer cell growth.
持續的減重有助於降低脂肪組織中的雌激素生成，而這些藥物減輕全身性發炎以及改善胰島素阻抗的能力，也可能阻礙癌細胞的生長。
These studies are observational and do not confirm that the drugs themselves prevent cancer; unmeasured factors like lifestyle habits could play a role.
這些研究屬於觀察性研究，並無法確認這些藥物本身就能預防癌症；諸如生活習慣等未經測量的因素可能也扮演了某種角色。
These findings represent an important starting point for future research, but the drugs are not currently recommended for cancer prevention.
這些發現為未來的研究奠定了重要的基礎，但目前並不建議將這些藥物用於癌症預防。
As always, consult your doctor regarding personal health decisions.
一如既往，有關個人健康決策，請務必諮詢您的醫生。
